Design Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC small-molecule candidates for inherited nucleotide repeat expansion diseases. It has no approved products and reported no product revenue.
Financial results and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Research and development expense | $11.3 million | $5.0 million | $20.1 million | $8.9 million |
| General and administrative expense | $4.3 million | $2.7 million | $9.0 million | $4.5 million |
| Total operating expenses | $15.6 million | $7.7 million | $29.0 million | $13.4 million |
| Net loss | $15.0 million | $7.6 million | $28.3 million | $13.2 million |
| Basic and diluted net loss per share | $0.27 | $0.14 | $0.51 | $0.36 |
- Q2 operating expenses approximately doubled year over year. Management attributed higher R&D spending mainly to DT-216 clinical development, early-stage programs and increased staffing; higher G&A reflected staffing, stock-based compensation and public-company costs.
- Cash used in operations was $22.3 million for the first half, versus $12.0 million in the prior-year period. The filing reports no operating revenue or positive operating cash flow.
- At June 30, cash and cash equivalents were $119.7 million and investment securities were $239.7 million, totaling $359.4 million, compared with $384.1 million at December 31, 2021. The decline in cash largely reflected operating use and purchases of securities; investing cash outflow was $156.5 million, primarily securities purchases.
- Total assets were $367.9 million; total liabilities were $10.8 million, including $4.0 million of operating lease liabilities. The balance sheet reports no debt. Stockholders’ equity was $357.2 million.
- Available-for-sale securities had $2.3 million of unrealized losses at quarter-end, which management attributed primarily to interest-rate changes; no credit-loss allowance was recorded. The company stated a hypothetical 100-basis-point rate change would not materially affect its financial statements.
- Margins are not meaningful for this pre-revenue company; the filing reports no sales or gross profit.
Pipeline, outlook and material developments
- The FDA cleared the IND for lead Friedreich ataxia candidate DT-216 in February 2022. The first single-ascending-dose cohort of its Phase 1 trial was dosed in March. The FDA granted DT-216 Fast Track designation; management expected initial topline clinical data in Q4 2022.
- For myotonic dystrophy type 1, management expected to complete IND-enabling studies and seek regulatory clearance for a first-in-human trial in 2023. The Fuchs endothelial corneal dystrophy program remained in preclinical research.
- Management expected current cash, cash equivalents and investments to fund planned expenses and capital requirements for more than 12 months after the filing. It also cautioned that resources would not fund candidates through regulatory approval and that substantial additional capital would be needed. Future financing could dilute shareholders or require unfavorable terms or strategic concessions.
- An effective 2022 shelf registration allows up to $300 million of securities, including up to $100 million through an at-the-market program; no ATM shares had been sold by June 30, 2022.
- The company recorded a $0.1 million WARF payment upon U.S. IND acceptance during the first half. Further regulatory and commercial milestones could total up to $17.5 million, in addition to potential royalties and sublicense fees.
- A related-party lease was amended in March 2022 to add approximately 4,900 square feet of office space. The Executive Chairperson is the landlord entity’s sole member and manager. The company also disclosed related-party consulting arrangements, including a $240,000 potential termination fee under one agreement; no liability was recorded for that fee.
- Management cited clinical and regulatory uncertainty, possible adverse effects, patient enrollment, reliance on third-party research and manufacturing, intellectual-property protection, competition, and macroeconomic, inflation, supply-chain and COVID-19 risks. It reported no material contingent liabilities or litigation expected to materially harm the business.
- Disclosure controls were deemed effective. The company implemented a new ERP system in Q2 and modified or added certain internal controls.
Key facts investors should verify
- Whether DT-216’s Phase 1 progress, safety findings and data timing matched management’s Q4 2022 expectation; the filing’s forward-looking statements do not guarantee outcomes.
- Subsequent operating cash use, investment balances and whether the stated runway remains supported by actual spending and development plans.
- Financing plans and any use of the shelf or ATM program, including potential dilution and financing terms.
- Progress toward DM1 IND-enabling work and the stated 2023 regulatory objective.
- Related-party lease and consulting terms, and potential WARF milestone, royalty and sublicense obligations.